Tags

Type your tag names separated by a space and hit enter

Expression of luminal and basal cytokeratins in human breast carcinoma.
J Pathol. 2004 Jun; 203(2):661-71.JP

Abstract

We have examined basal and luminal cell cytokeratin expression in 1944 cases of invasive breast carcinoma, using tissue microarray (TMA) technology, to determine the frequency of expression of each cytokeratin subtype, their relationships and prognostic relevance, if any. Expression was determined by immunocytochemistry staining using antibodies to the luminal cytokeratins (CKs) 7/8, 18 and 19 and the basal markers CK 5/6 and CK 14. Additionally, assessment of alpha-smooth muscle actin (SMA) and oestrogen receptor status (ER) was performed. The vast majority of the cases showed positivity for CK 7/8, 18 and 19 indicating a differentiated glandular phenotype, a finding associated with good prognosis, ER positivity and older patient age. In contrast, basal marker expression was significantly related to poor prognosis, ER negativity and younger patient age. Multivariate analysis showed that CK 5/6 was an independent indicator for relapse free interval. We were able to subgroup the cases into four distinct phenotype categories (pure luminal, mixed luminal/basal, pure basal and null), which had significant differences in relation to the biological features and the clinical course of the disease. Tumours classified as expressing a basal phenotype (the combined luminal plus basal and the pure basal) were in a poor prognostic subgroup, typically ER negative in most cases. These findings provide further evidence that breast cancer has distinct differentiation subclasses that have both biological and clinical relevance.

Authors+Show Affiliations

Department of Histopathology, Breast Unit, Nottingham City Hospital NHS Trust and University of Nottingham, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15141381

Citation

Abd El-Rehim, Dalia M., et al. "Expression of Luminal and Basal Cytokeratins in Human Breast Carcinoma." The Journal of Pathology, vol. 203, no. 2, 2004, pp. 661-71.
Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203(2):661-71.
Abd El-Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J., Blamey, R. W., Robertson, J. F., Nicholson, R. I., & Ellis, I. O. (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. The Journal of Pathology, 203(2), 661-71.
Abd El-Rehim DM, et al. Expression of Luminal and Basal Cytokeratins in Human Breast Carcinoma. J Pathol. 2004;203(2):661-71. PubMed PMID: 15141381.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of luminal and basal cytokeratins in human breast carcinoma. AU - Abd El-Rehim,Dalia M, AU - Pinder,Sarah E, AU - Paish,Claire E, AU - Bell,J, AU - Blamey,R W, AU - Robertson,John F R, AU - Nicholson,Robert I, AU - Ellis,Ian O, PY - 2004/5/14/pubmed PY - 2004/7/20/medline PY - 2004/5/14/entrez SP - 661 EP - 71 JF - The Journal of pathology JO - J Pathol VL - 203 IS - 2 N2 - We have examined basal and luminal cell cytokeratin expression in 1944 cases of invasive breast carcinoma, using tissue microarray (TMA) technology, to determine the frequency of expression of each cytokeratin subtype, their relationships and prognostic relevance, if any. Expression was determined by immunocytochemistry staining using antibodies to the luminal cytokeratins (CKs) 7/8, 18 and 19 and the basal markers CK 5/6 and CK 14. Additionally, assessment of alpha-smooth muscle actin (SMA) and oestrogen receptor status (ER) was performed. The vast majority of the cases showed positivity for CK 7/8, 18 and 19 indicating a differentiated glandular phenotype, a finding associated with good prognosis, ER positivity and older patient age. In contrast, basal marker expression was significantly related to poor prognosis, ER negativity and younger patient age. Multivariate analysis showed that CK 5/6 was an independent indicator for relapse free interval. We were able to subgroup the cases into four distinct phenotype categories (pure luminal, mixed luminal/basal, pure basal and null), which had significant differences in relation to the biological features and the clinical course of the disease. Tumours classified as expressing a basal phenotype (the combined luminal plus basal and the pure basal) were in a poor prognostic subgroup, typically ER negative in most cases. These findings provide further evidence that breast cancer has distinct differentiation subclasses that have both biological and clinical relevance. SN - 0022-3417 UR - https://www.unboundmedicine.com/medline/citation/15141381/Expression_of_luminal_and_basal_cytokeratins_in_human_breast_carcinoma_ L2 - https://doi.org/10.1002/path.1559 DB - PRIME DP - Unbound Medicine ER -